Payment overview · 2025
General Payments
$11,052.41
41 reported records · 14 companies
Healthcare provider profile · identity verified
Kyle M Markel, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · DETROIT, MI · NPI 1982086682
Verified facts
What the public records show
CMS Open Payments records show Kyle M Markel, MD received $11,052.41 in general payments during 2025 across 41 reported records.
AngioDynamics, Inc. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $4,972.22 | 45.0% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $2,830.76 | 25.6% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,400.74 | 21.7% | 13 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $208.63 | 1.9% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $147.00 | 1.3% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $144.08 | 1.3% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $111.15 | 1.0% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $75.80 | 0.7% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $35.98 | 0.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.63 | 0.3% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $27.47 | 0.2% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $26.58 | 0.2% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $23.27 | 0.2% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $14.10 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $4,972.22 | 1 |
| Food and Beverage | $3,798.62 | 35 |
| Travel and Lodging | $2,281.57 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $4,972.22 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,605.56 | 5 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $764.80 | 4 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $423.80 | 4 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $407.66 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $231.80 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $231.80 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $190.47 | 2 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $181.30 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $147.00 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $147.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $144.08 | 1 | 2025 |
Source payment records
|
|||||
| WavelinQ Normalized: wavelinq |
Device | Bard Peripheral Vascular, Inc. | $111.15 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Normalized: enroute enflate transcarotid rx balloon dilatation catheter |
Device | Boston Scientific Corporation | $98.15 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $82.76 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $75.80 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $75.80 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $75.80 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $34.63 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| PROLENE Normalized: prolene |
Device | Ethicon US, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 121 | 46 |
| Xarelto | Rivaroxaban | 48 | 11 |
| Eliquis | Apixaban | 44 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,052.41 · 41 records | AngioDynamics, Inc. | AFX2 Bifurcated Endograft System, Alto Abdominal Stent Graft System, Auryon Laser System 100-120 Vac, CT THROMBECTOMY SYSTEM KIT, ENDOCROSS Device, ENDURANT IIS, ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, EVARREST, FLOWTRIEVER CATHETER, S, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, General - Therapies, General - Vascular Intervention, Integra, Integra Dermal Regeneration Template, Kerecis GraftGuide, Kerecis SurgiClose, LYMPHA PRESS OPTIMAL PLUS(US) BT, PCD-51 731A (US) - White, PCD-52 737A (US) White, PRIMATRIX, PRODIGY CATHETER, PROLENE, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, SYMPHONY CATHETER, Torus Stent Graft System, V.A.C.ULTA, VISTASEAL, WavelinQ | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error